Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department

Academic Emergency Medicine

Volumn 18, Issue 7, 2011, Pages 745-753

  Dowdy, David W ^a   Rodriguez, Robert M ^a,c   Bradley Hare, C ^b   Kaplan, Beth ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; EMERGENCY HEALTH SERVICE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; TARGETED HUMAN IMMUNODEFICIENCY VIRUS TEST; URBAN AREA;

ADULT; CALIFORNIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HIV INFECTIONS; HOSPITALS, URBAN; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 79960526373     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2011.01110.x     Document Type: Article

References (44)

1. Campsmith ML, Rhodes PH, Hall HI, Green TA,. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010; 53: 619-24.
2. Marks G, Crepaz N, Janssen RS,. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006; 20: 1447-50. (Pubitemid 43948252)
3. Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH,. Opt out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA. 2008; 300: 945-51.
4. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. 2006; 55: RR-14.
5. Paltiel AD, Weinstein MC, Kimmel AD, et al., Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005; 352: 586-95. (Pubitemid 40204671)
6. Sanders GD, Bayoumi AM, Sundaram V, et al., Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005; 352: 570-85. (Pubitemid 40204670)
7. Holtgrave DR,. Costs and consequences of the U.S. Centers for Disease Control and Prevention's recommendations for opt-out HIV testing. PLoS Med. 2007; 4: e194.
8. Hanssens C,. Legal and ethical implications of optout testing. Clin Infect Dis. 2007; 45 (Suppl 4): S232-9. (Pubitemid 351417222)
9. Lifson AR, Rybicki SL,. Routine opt-out HIV testing. Lancet. 2007; 369: 539-40. (Pubitemid 46241425)
10. Dibosa-Osadolor O, Roberts T,. Economic evaluation, human immunodeficiency virus infection and screening: a review and critical appraisal of economic studies. Int J Technol Assess Health Care. 2010; 26: 301-8.
11. Fenton KA,. Changing epidemiology of HIV/AIDS in the United States: implications for enhancing and promoting HIV testing strategies. Clin Infect Dis. 2007; 45 (Suppl 4): S213-20. (Pubitemid 351417219)
12. Centers for Disease Control and Prevention. Missed opportunities for earlier diagnosis of HIV infection - South Carolina, 1997-2005. MMWR Morb Mortal Wkly Rep. 2006; 55: 1269-72.
13. Haukoos JS, Hopkins E, Conroy AA, et al., Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA. 2010; 304: 284-92.
14. Haukoos JS, Hopkins E, Eliopoulos VT, et al., Development and implementation of a model to improve identification of patients infected with HIV using diagnostic rapid testing in the emergency department. Acad Emerg Med. 2007; 14: 1149-57. (Pubitemid 350130332)
15. Centers for Disease Control and Prevention. Rapid HIV testing in emergency departments - three US sites, January 2005-March 2006. MMWR. 2007; 56: 597-601.
16. Lyss SB, Branson BM, Kroc KA, Couture EF, Newman DR, Weinstein RA,. Detecting unsuspected HIV infection with a rapid whole-blood HIV test in an urban emergency department. J Acquir Immune Defic Syndr. 2007; 44: 435-42. (Pubitemid 46555379)
17. White DA, Scribner AN, Schulden JD, Branson BM, Heffelfinger JD,. Results of a rapid HIV screening and diagnostic testing program in an urban emergency department. Ann Emerg Med. 2009; 54: 56-64.
18. Ehrenkranz PD, Ahn CJ, Metlay JP, Camargo CA Jr, Holmes WC, Rothman R,. Availability of rapid human immunodeficiency virus testing in academic emergency departments. Acad Emerg Med. 2008; 15: 144-50.
19. McKenna M,. HIV testing: should the emergency department take part? Ann Emerg Med. 2007; 49: 190-2.
20. Johns B, Baltussen R, Hutubessy R,. Programme Costs in the Economic Evaluation of Health Interventions. Cost Eff Resour Alloc. Available at:. Accessed May 5, 2011.
21. Salary.com. Salary Wizard. Available at:. Accessed May 5, 2011.
22. Centers for Disease Control and Prevention. FDA-Approved Rapid HIV Antibody Screening Tests. Available at:. Accessed May 5, 2011.
23. Association for the Advancement of Cost Engineering. Parametric Cost Estimating Model for Buildings. Available at:. Accessed May 25, 2011. Pay access only.
24. Cole-Parmer. Megafuge 11R product detail [discontinued product]. Available at: =. Accessed May 5, 2011.
25. Paltiel AD, Walensky RP, Schackman BR, et al., Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006; 145: 797-806. (Pubitemid 351650333)
26. U.S. Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers. Available at:. Accessed November 1, 2010.
27. Gold MR, Siegel JE, Russell LB, Weinstein MC,. Cost-effectiveness in Health and Medicine: Report of the Panel on Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.
28. Schackman BR, Gebo KA, Walensky RP, et al., The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006; 44: 990-7. (Pubitemid 44674030)
29. Honiden S, Sundaram V, Nease RF, et al., The effect of diagnosis with HIV infection on health-related quality of life. Qual Life Res. 2006; 15: 69-82. (Pubitemid 43102473)
30. Holtgrave DR,. Potential and limitations of a "test and treat" strategy as HIV prevention in the United States. Int J Clin Pract. 2010; 64: 678-81.
31. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Vol. 19. Available at:. Accessed May 5, 2011.
32. Pinkerton SD, Holtgrave DR, Galletly CL,. Infections prevented by increasing HIV serostatus awareness in the United States, 2001 to 2004. J Acquir Immune Defic Syndr. 2008; 47: 354-7. (Pubitemid 351619423)
33. Marks G, Crepaz N, Senterfitt JW, Janssen RS,. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005; 39: 446-53. (Pubitemid 41003791)
34. Porco TC, Martin JN, Page-Shafer KA, et al., Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004; 18: 81-8. (Pubitemid 38402321)
35. Quinn TC, Wawer MJ, Sewankambo N, et al., Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342: 921-9. (Pubitemid 30177052)
36. Donnell D, Baeten JM, Kiarie J, et al., Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010; 375: 2092-8.
37. Holtgrave DR, Pinkerton SD,. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16: 54-62.
38. Neumann PJ, Sandberg EA, Bell CM, et al., Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood). 2000; 19: 92-109.
39. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS,. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008; 46: 349-56.
40. Attia S, Egger M, Müller M, Zwahlen M, Low N,. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009; 23: 1397-404.
41. Kamb ML, Fishbein M, Douglas JM Jr, et al., Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998; 280: 1161-7. (Pubitemid 28457806)
42. Koo DJ, Begier EM, Henn MH, Sepkowitz KA, Kellerman SE,. HIV counseling and testing: less targeting, more testing. Am J Public Health. 2006; 96: 962-4. (Pubitemid 43825259)
43. Thompson MA, Aberg JA, Cahn P, et al., Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304: 321-33.
44. Schackman BR, Freedberg KA, Weinstein MC, et al., Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002; 162: 2478-86. (Pubitemid 35340465)